Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT03702088 | Place of the Hevylite Test in the Evaluation of MRD in Myeloma | unknown | — | 124 | University Hospital, MontpellierOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04122092 | Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma(EUCADD) | unknown | — | 100 | Shanghai Changzheng HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04162119 | Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02387879 | A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR | unknown | — | 500 | CelgeneINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT04065308 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma(Dara_DCEP) | unknown | Phase 2 | 33 | Seoul National University HospitalOTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT04063189 | Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | unknown | Phase 2 | 100 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT03815383 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04004338 | Carfilzomib in Combination for the Treatment of RR MM | unknown | — | 300 | Black Sea Hematology AssociationOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT02976272 | Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple(SENSIB) | unknown | — | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992170 | Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive(DART4MM) | unknown | Phase 2 | 50 | Azienda Ospedaliera Universitaria SeneseOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03931421 | B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03751293 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03093168 | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | unknown | Phase 1 | 10 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT01240525 | Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers(ProT4) | unknown | Phase 2 | 114 | University College, LondonOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03697655 | Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma(PREDATOR) | unknown | Phase 2 | 274 | Polish Myeloma ConsortiumOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03792620 | Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation(MAXDARA) | unknown | Phase 3 | 20 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03776331 | Vascular Functions in Myeloma Patients During Anti-tumor Therapy | unknown | — | 96 | University Hospital, EssenOTHER | 0 | Dec 19, 2018 | clinicaltrials |
| NCT03672253 | CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma | unknown | Phase 1 | 20 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03674463 | LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma | unknown | Phase 1 | 10 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT03746652 | Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(DARIA) | unknown | Phase 2 | 50 | Hellenic Society of HematologyOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT03601624 | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans(MM-POM-2018) | unknown | Phase 2 | 18 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del EstadoOTHER_GOV | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03704597 | Cryotherapy Against Oral Mucositis After High-dose Melphalan | unknown | N/A | 100 | Sahlgrenska University HospitalOTHER | 0 | Oct 15, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03664661 | BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02187731 | Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma(FULIMA) | unknown | — | 70 | Odense University HospitalOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02572492 | Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support(CARFI) | unknown | Phase 2 | 200 | Henrik GregersenOTHER | 5 | Aug 17, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT03605056 | Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | unknown | Phase 2 | 25 | Peng LiuOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03556748 | WB-EMS and Nutrition in Patients With Hematological Malignancies | unknown | N/A | 40 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Jun 14, 2018 | clinicaltrials |
| NCT01554852 | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients(Myeloma XI) | unknown | Phase 3 | 4,420 | University of LeedsOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT03143036 | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 4 | Jun 7, 2018 | clinicaltrials |
| NCT02158702 | Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03515915 | Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment | unknown | — | 30 | University Hospital, MontpellierOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT02559154 | Modified Bortezomib-based Combination Therapy for Multiple Myeloma | unknown | Phase 4 | 80 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT02955810 | Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)(CyBorD-Dara) | unknown | Phase 1 | 18 | National University of Ireland, Galway, IrelandOTHER | 1 | Mar 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 4, 2019source: clinicaltrials